Semi-automatic 3D-volumetry of liver metastases from neuroendocrine tumors to improve combination therapy with 177Lu-DOTATOC and 90Y-DOTATOC

Semi-automatic 3D-volumetry of liver metastases from neuroendocrine tumors to improve combination therapy with 177Lu-DOTATOC and 90Y-DOTATOC

PURPOSEPatients with neuroendocrine tumors (NET) often present with disseminated liver metastases and can be treated with a number of different nuclides or nuclide combinations in peptide receptor radionuclide therapy (PRRT) depending on tumor load and lesion diameter. For quantification of dissemin...

Full description

Bibliographic Details
Main Authors:	Matthaeus Cieciera, Clemens Kratochwil, Jan Moltz, Hans-Ulrich Kauczor, Tim Holland-Letz, Peter Choyke, Walter Mier, Uwe Haberkorn, Frederik L. Giesel
Format:	Article
Language:	English
Published:	Galenos Publishing House 2016-05-01
Series:	Diagnostic and Interventional Radiology
Online Access:	http://www.dirjournal.org/archives/archive-detail/article-preview/semi-automatic-3d-volumetry-of-liver-metastases-fr/55480

Similar Items

Extravasation of [177Lu]Lu-DOTATOC: case report and discussion
by: Anne Kirstine Arveschoug, et al.
Published: (2020-06-01)

<sup>90</sup>Y/<sup>177</sup>Lu-DOTATOC: From Preclinical Studies to Application in Humans
by: Licia Uccelli, et al.
Published: (2021-09-01)

Biokinetic and dosimetry of 90y-dotatoc therapy for neuroendocrine tumours
by: Krstić Dragana, et al.
Published: (2017-01-01)

The Dependence of Renal <sup>68</sup>Ga[Ga]-DOTATOC Uptake on Kidney Function and Its Relevance for Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu[Lu]-DOTATOC
by: Falk Gühne, et al.
Published: (2021-07-01)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
by: Peter Frøhlich Staanum, et al.
Published: (2021-11-01)

[<sup>68</sup>Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [<sup>177</sup>Lu]DOTATOC PRRT: The “Theragnomics” Concept
by: Riccardo Laudicella, et al.
Published: (2022-02-01)

First intraindividual comparison of contrast-enhanced MRI, FET- and DOTATOC- PET in patients with intracranial meningiomas
by: Jan Oliver Dittmar, et al.
Published: (2017-11-01)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses
by: Myrna Luna-Gutiérrez, et al.
Published: (2023-07-01)

Glucose Metabolism Modification Induced by Radioligand Therapy with [<sup>177</sup>Lu]Lu/[<sup>90</sup>Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial
by: Luca Urso, et al.
Published: (2022-09-01)

Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [<sup>177</sup>Lu]Lu-DOTATOC
by: Markus Galler, et al.
Published: (2022-03-01)

The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [<sup>177</sup>Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis
by: Tristan Ruhwedel, et al.
Published: (2021-02-01)

Influence of 68Ga-DOTATOC on sparing of normal tissue for radiation therapy of skull base meningioma: differential impact of photon and proton radiotherapy
by: Falk Stade, et al.
Published: (2018-04-01)

The utility of gallium-68 DOTATOC PET/CT in lymphangioleiomyomatosis
by: Brian Gaffney, et al.
Published: (2021-10-01)

Calculation of absorbed dose due to the 90Y-DOTATOC peptide receptor radionuclide therapy by MCNP5/X
by: Jeremić Marija Ž., et al.
Published: (2018-01-01)

Pindborg Tumor—An Uncommon Odontogenic Tumor Detected by 68Ga-DOTATOC
by: Anna Herden, et al.
Published: (2022-02-01)

Improved radiolabeling of DOTATOC with trivalent radiometals for clinical application by addition of ethanol
by: Elisabeth Eppard, et al.
Published: (2016-04-01)

Evaluation of the Possible Utilization of 68Ga-DOTATOC in Diagnosis of Adenocarcinoma Breast Cancer
by: Hassan Yousefnia, et al.
Published: (2018-01-01)

Gastroenteropancreatic Neuroendocrine Tumors: Standardizing Therapy Monitoring with Ga-DOTATOC PET/CT Using the Example of Somatostatin Receptor Radionuclide Therapy
by: Wolfgang Luboldt, et al.
Published: (2010-11-01)

Prospective study of dynamic whole-body 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors
by: Philippe Thuillier, et al.
Published: (2021-03-01)

Dual Tracer 68Ga-DOTATOC and 18F-FDG PET Improve Preoperative Evaluation of Aggressiveness in Resectable Pancreatic Neuroendocrine Neoplasms
by: Paola Mapelli, et al.
Published: (2021-01-01)

[<sup>68</sup>Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning
by: Bamberg Michael, et al.
Published: (2009-11-01)

Usefulness of 68Ga-DOTATOC PET/CT to localize the culprit tumor inducing osteomalacia
by: Dong Yun Lee, et al.
Published: (2021-01-01)

Correction: 68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
Published: (2022-05-01)

Intrapancreatic accessory spleen false positive to 68Ga-Dotatoc: case report and literature review
by: Francesco Lancellotti, et al.
Published: (2019-07-01)

Predictive and Prognostic Role of Pre-Therapy and Interim 68Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRT
by: Rexhep Durmo, et al.
Published: (2022-01-01)

68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan
by: Shih-Hsin Chen, et al.
Published: (2018-06-01)

Comparison of diagnostic value of 68 Ga-DOTATOC PET/MRI and standalone MRI for the detection of intracranial meningiomas
by: Heike C. Einhellig, et al.
Published: (2021-04-01)

An exceptional response to 177LuPSMA undermined by neuroendocrine transformation
by: Pretoria Bilinski, et al.
Published: (2021-01-01)

Increased x-ray attenuation in malignant vs. benign mediastinal nodes in an orthotopic model of lung cancer
by: Paul Flechsig, et al.
Published: (2016-01-01)

Diagnostic Impact of Dual-Time PET/CT with <sup>68</sup>Gallium-PSMA in Prostate Cancer and <sup>68</sup>Gallium-DOTATOC in Neuroendocrine Tumors
by: Damiano Librizzi, et al.
Published: (2023-03-01)

Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient
by: Manuel Weber, et al.
Published: (2020-04-01)

Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
by: Mohid S. Khan, et al.
Published: (2021-11-01)

Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [<sup>177</sup>Lu]Lu-DOTA-TATE or [<sup>177</sup>Lu]Lu-DOTA-TATE and [<sup>90</sup>Y]Y-DOTA-TATE—A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
by: Adam Daniel Durma, et al.
Published: (2023-11-01)

[18F]FDOPA PET/CT is superior to [68Ga]DOTATOC PET/CT in diagnostic imaging of pheochromocytoma
by: Peter Iversen, et al.
Published: (2023-12-01)

Optic Nerve Sheath Meningiomas: Solving Diagnostic Challenges with <sup>68</sup>Ga-DOTATOC PET/CT
by: Tatiana Horowitz, et al.
Published: (2023-07-01)

Preclinical Studies of 68Ga-DOTATOC: Biodistribution Assessment in Syrian Rats and Evaluation of Absorbed Dose in Human Organs
by: mojdeh naderi, et al.
Published: (2016-01-01)

Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour
by: Sejin Ha, et al.
Published: (2024-02-01)

Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by 68Ga-DOTATOC PET/CT
by: Ulrika Jahn, et al.
Published: (2021-11-01)

Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT
by: Schreiter Nils Friedemann, et al.
Published: (2014-12-01)

Shortened Tracer Uptake Time in GA-68-DOTATOC-PET of Meningiomas Does Not Impair Diagnostic Accuracy and PET Volume Definition
by: Josefine Graef, et al.
Published: (2020-12-01)